Next-Generation Imaging

Novel Theranostic Radiopharmaceutical Detects Lesions in Patients With PSMA PET-Negative BCR Prostate Cancer
Results of the phase 2 diagnostic investigator-initiated trial of 64Cu SAR-Bombesin in prostate cancer (BOP) have shown the novel theranostic radiopharmaceutical can detect lesions in men with biochemically recurrent (BCR) prostate cancer that are either negative or equivocal on prostate-specific membrane antigen positron emission tomography (PSMA PET). ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Prostate Cancer
Prostate Cancer

Conference Coverage

Advertisement
Trending

Advertisement